First Tracks Biotherapeutics, Inc. (TRAX)
Market Closed
15 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary 
XDUS $
17. 88
+0.24
+1.3605%
After Hours
$
+1.17 +6.5436% 19. 05
579.21M Market Cap
- P/E Ratio
- Div Yield
93,013 Volume
- Eps
$ 17.64
Previous Close Want to track TRAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away.
Seekingalpha | 1 month ago
